AI Verdict
PCRX has stronger fundamentals based on our AI analysis.
PCRX vs PBSV Fundamental Comparison
| Metric | PCRX | PBSV |
|---|---|---|
| Revenue | $726.4M | $2.3M |
| Net Income | $7.0M | $32,860.0 |
| Net Margin | 1.0% | 1.4% |
| ROE | 1.0% | 0.3% |
| ROA | 0.6% | 0.2% |
| Current Ratio | 4.54x | 4.03x |
| Debt/Equity | 0.54x | 0.00x |
| EPS | $0.16 | $0.00 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
PCRX vs PBSV: Frequently Asked Questions
Is PCRX or PBSV a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), PCRX has stronger fundamentals. PCRX is rated HOLD (65% confidence) while PBSV is rated SELL (78% confidence). This is not investment advice.
How does PCRX compare to PBSV fundamentally?
Pacira BioSciences, Inc. has ROE of 1.0% vs Pharma-Bio Serv, Inc.'s 0.3%. Net margins are 1.0% vs 1.4% respectively.
Which stock pays higher dividends, PCRX or PBSV?
PCRX has a dividend yield of N/A or no dividend while PBSV has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in PCRX or PBSV for long term?
For long-term investing, consider that PCRX has HOLD rating with 65% confidence, while PBSV has SELL rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about PCRX vs PBSV?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For PCRX vs PBSV, the AI consensus favors PCRX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.